March 28, 2025 07:30 AM EDT

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

Kyle LaHucik

Senior Reporter

Novo Nordisk is going all-in on next-generation obesity medicines, and on Friday announced a licensing deal with a Texas biotech to get access to its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

Vertex’s second-generation diabetes cell therapy fails early-stage study

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

European regulator rejects Lilly's Alzheimer’s drug over potentially fatal side effects

No­vo inks sec­ond obe­si­ty deal of the week, with Lex­i­con oral drug part­ner­ship worth up to $1B

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

FDA's Pe­ter Marks re­signs, say­ing he won't ac­cept Kennedy's 'mis­in­for­ma­tion and lies'

Blue­bird gets new M&A bid, seek­ing to top pri­vate eq­ui­ty of­fer

BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer

Ver­tex’s sec­ond-gen­er­a­tion di­a­betes cell ther­a­py fails ear­ly-stage study

‘Peo­ple will die’: End of NIH grants guts work be­tween aca­d­e­mics and com­pa­nies to counter next pan­dem­ic

Eu­ro­pean reg­u­la­tor re­jects Lil­ly's Alzheimer’s drug over po­ten­tial­ly fa­tal side ef­fects

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

Vertex’s second-generation diabetes cell therapy fails early-stage study

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

European regulator rejects Lilly's Alzheimer’s drug over potentially fatal side effects